Partnership expands UK contamination control capabilities
Facility Monitoring Systems Ltd (FMS), part of the Trescal group, has signed a strategic UK partnership with Denmark-based UV Medico to supply and support its full range of Far-UVC (222 nm) disinfection systems.
Far-UVC is a mercury-free, chemical-free technology designed to inactivate airborne pathogens with high effi ciency - up to 99.9% - including viruses such as SARS-CoV-2. Operating at a wavelength of 222 nanometres using Krypton-Chloride excimer lamps, the UV Medico platform delivers continuous, human-safe decontamination of air and surfaces in critical cleanroom and healthcare settings.
The agreement complements FMS’s existing portfolio of viable and non-viable environmental monitoring solutions, offering a combined
approach to bioburden risk reduction in high-grade cleanrooms, aseptic manufacturing spaces and other regulated environments.
“Partnering with UV Medico enables us to integrate validated Far- UVC technology into contamination control strategies across life science, pharmaceutical, biotech and healthcare sectors,” said Deborah Haisman, Commercial Director at FMS. “Incorporating this with real-time monitoring will allow customers to further reduce microbial load in critical spaces, while also opening up opportunities in advanced manufacturing, semiconductor, and space assembly sectors where cleanroom compliance is essential.”
UV Medico’s UV222 devices also have wide applicability in public healthcare, food service, transport, and hygiene-sensitive environments,
offering rapid, continuous disinfection even in occupied spaces.
Peter Johansen, CEO at UV Medico, added: “Combining our Far-UVC technology with FMS’s expertise and support network enables us to deliver compliant, fully integrated decontamination solutions tailored to the needs of UK customers.”
The partnership supports both companies’ commitment to delivering innovative, validated contamination control technologies to meet growing demand across critical sectors.
More information online:
ilmt.co/PL/m6Qm 65232pr@reply-direct.com
New leadership to drive growth in TIDES
EcoVadis silver medal recognises commitment to sustainability
Lauda Dr R. Wobser GmbH & Co KG, a global leader in temperature control systems, has earned a silver medal from EcoVadis, ranking among the top 15% of companies worldwide with a score of 70 out of 100.
EcoVadis evaluates fi rms on 21 sustainability criteria covering environment, labour and human rights, ethics, and sustainable procurement - based on international standards including the UN Global Compact and ISO 26000. Over 85,000 companies have been assessed globally.
This award recognises Lauda’s strong sustainability management and strategic initiatives. “This confi rms our belief that sustainable business and success go hand in hand,” said Dr Gunther Wobser, Lauda’s President & CEO. “It’s a key milestone in our sustainability journey.”
A major factor was Lauda’s 2023 sustainability report, published in late 2024, which transparently documented its environmental, social, and governance (ESG) efforts. “Clear reporting of our ESG actions was vital to the assessment,” explained Dr Marc Stricker, Managing Director and head of quality and environmental management.
Lauda also enhanced sustainability policies, expanded data collection, and produced comprehensive reports - including a CSRD report aligned with new European standards - strengthening internal processes and transparency.
“We’re proud these efforts led to measurable progress,” added Dr Stricker, “validating our strategic approach.”
Looking ahead, Lauda will use EcoVadis insights in customer dialogue and continue refi ning its sustainability strategy and ESG reporting.
Dr Matteo Villain
Veranova has appointed Dr Matteo Villain as Vice President of Peptides and Oligonucleotides, strengthening its presence in the TIDES (peptides and oligonucleotides) sector.
Dr Villain brings extensive experience across the development and manufacturing lifecycle of peptide APIs, including process development, scale-up, cGMP production, validation, and regulatory compliance. He has led the development of over 60 peptide APIs and held senior leadership roles at Bachem Americas, Inc, including VP of Research and Development, VP of GMP Manufacturing, and VP of CMC Development. More recently, he served as Vice President and Global Peptides Technical Lead at Piramal Pharma Solutions and founded MV API Consulting.
“Dr Villain’s holistic expertise in peptide API development and manufacturing will be a tremendous asset to Veranova,” said Rohtash Kumar, Senior VP of Development Operations and Chief Technology Offi cer. “This strategic hire supports our ongoing investments in bioconjugation, HPAPI, and ADC expansion, helping us advance our initiatives in the TIDES space.”
Dr Villain holds a Doctorate in Medicinal Chemistry and Pharmaceutical Science from the University of Milan and completed postdoctoral fellowships at The University
of
Alabama (Birmingham) and the University of Geneva. He has shared his expertise at industry events including Tides USA and US Pharmacopeia (USP) workshops.
More information online:
ilmt.co/PL/Gw3W 65549pr@reply-direct.com
Oxford collaboration to advance oral vaccine delivery
Upperton Pharma Solutions is collaborating with the University of Oxford’s Pandemic Sciences Institute on the development of an oral formulation for adenovirus-vectored vaccines. The project, supported through the fi rst VaxHub Sustainable Platform Funding Call, with support from the UK’s Vaccines Manufacturing and Innovation Centre, aims to address the limitations of traditional intramuscular administration.
By exploring oral delivery routes, the research team hopes to induce mucosal immunity, improve vaccine stability, simplify distribution, and allow self-administration. Upperton will contribute its expertise in oral dosage form development, particle engineering, and spray drying to advance the formulation.
“Oral vaccine delivery has the potential to transform global immunisation and pandemic response strategies,” said Richard Johnson, Chief Scientifi c Offi cer at Upperton. “This project is a signifi cant step forward where we can apply our formulation development expertise.”
The work is led by Professor Dame Sarah Gilbert at Oxford’s Pandemic Sciences Institute and is expected to complete in summer 2026.
Funding from the UK Engineering and Physical Sciences Research Council (EPSRC) for the Manufacturing Research Hub for a Sustainable Future (VaxHub Sustainable), co-directed by University College London and the University of Oxford with UK university partners, is gratefully acknowledged (Grant Reference: EP/X038181/1).
More information online:
ilmt.co/PL/9M41 65560pr@reply-direct.com
Lauda received the EcoVadis Silver Medal in March 2025. © LAUDA
More information online:
ilmt.co/PL/37Z1 65358pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
